1

Organon

#3195

Rank

$3.89B

Marketcap

US United States

Country

Organon
Leadership team

Mr. Kevin Ali (CEO & Director)

Mr. Matthew M. Walsh (Exec. VP & CFO)

Ms. Susanne Gabriele Fiedler (Exec. VP & Chief Commercial Officer)

Products/ Services
Health Care, Medical Device, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Oss, Noord-Brabant, The Netherlands
Established
2020
Company Registration
SEC CIK number: 0001821825
Net Income
1B - 20B
Revenue
Above - 1B
Traded as
OGN
Social Media
Overview
Location
Summary
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
History

Organon was founded by Dr. Saal van Zwanenberg in Oss, the Netherlands, in 1923 as a separate part of the meat factory Zwanenberg's fabrieken. Its first product was insulin in 1923. In the thirties it manufactured estrogens.In 1948, Organon acquired the Newhouse research site in Scotland, United Kingdom. The production of cortisone was initiated in 1953.In 1962, it bought the stock of the Nederlandsche Cocaïnefabriek. The company name was changed to Koninklijke Zwanenberg-Organon , and it merged with the fibre producer AKU in 1969 to become AKZO, later Akzo Nobel. Organon was the human health care business unit of Akzo Nobel. In 2004, Organon acquired active-pharmaceutical-ingredient producer Diosynth.In November 2007, Schering-Plough acquired Organon BioSciences and veterinary pharmaceutical company Intervet from Akzo Nobel. Schering-Plough transferred Organon to its headquarters in New Jersey. Two years later, Schering-Plough merged with Merck & Co., known as Merck Sharp & Dohme or MSD outside the United States and Canada.In May 2020, Merck & Co. announced that Organon & Co. will be the name of "the pending spin-off of its women’s health, legacy products, and biosimilars businesses, which the company says is on track to be completed by the end of the first half in 2021." Merck completed the spinoff and Organon & Co. became a publicly traded company on 3 June 2021.In November 2021, the business announced it would acquire Forendo Pharma and its lead compound, a potentially first-in-class oral 17?-hydroxysteroid dehydrogenase type 1 inhibitor.

Mission
Our mission is to deliver impactful medicines and solutions for a healthier every day.
Vision
We envision a better and healthier every day for every woman.
Key Team

Dr. Sandra Milligan J.D., M.D. (Exec. VP and Head of R&D)

Ms. Rachel A. Stahler (Exec. VP & Chief Information Officer)

Mr. Aaron Falcione (Exec. VP & Chief HR Officer)

Ms. Jennifer Halchak (VP of Investor Relations)

Mr. Joseph T. Morrissey Jr. (Exec. VP and Head of Manufacturing & Supply)

Mr. Vittorio Nisita (Exec. VP & Head of Global Bus. Services)

Mr. Kirke Weaver (Gen. Counsel & Corp. Sec.)

Recognition and Awards
Organon won 11 awards in 2022 and 3 awards in 2021. In 2022, Organon won for Best Company for Women 2022, Best CEO 2022, Best Company Culture 2022, Best Company Compensation, Happiest Employees, Best CEOs for Diversity 2022, Best CEOs for Women 2022, Best Operations Team 2022, Best HR Team 2022, Best Places to Work in New York 2022 and Best Global Culture 2022. In 2021, Organon won for Best Company for Diversity 2021, Best Company for Women 2021 and Best CEO 2021. Based on 10,240 ratings and 358 participants, employees at Organon are very satisfied with their work experience. The overall culture score, 83/100 or A+, incorporates employee ratings based on their feedback on the Professional Development, Executive Team, Meetings and more.
References
Organon
Leadership team

Mr. Kevin Ali (CEO & Director)

Mr. Matthew M. Walsh (Exec. VP & CFO)

Ms. Susanne Gabriele Fiedler (Exec. VP & Chief Commercial Officer)

Products/ Services
Health Care, Medical Device, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Oss, Noord-Brabant, The Netherlands
Established
2020
Company Registration
SEC CIK number: 0001821825
Net Income
1B - 20B
Revenue
Above - 1B
Traded as
OGN
Social Media